Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gut Microbiome in DLBCL Treated With Glofitamab
Sponsor: Peking Union Medical College Hospital
Summary
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Official title: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2026-04-01
Completion Date
2029-12-31
Last Updated
2026-03-27
Healthy Volunteers
No
Conditions
Interventions
Gut microbiome analysis
Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients.